INmune Bio, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David J. Moss
- Full Time Employees
- 21
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 225 NE Mizner Boulevard Boca Raton FL United States of America 33432
- IPO Date
- Feb 4, 2019
- CIK
- 0001711754
- Website
- inmunebio.com
- Similar Companies
- Business
- INmune Bio, Inc. (INMB) is a clinical-stage biotechnology company that develops immunotherapies reprogramming the innate immune system to treat cancer, Alzheimer's disease, and other inflammation-driven conditions; its three primary product platforms include the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform with XPro1595 (also known as XPro) for mild Alzheimer's disease, mild cognitive impairment, and treatment-resistant depression, as well as INB03 for cancer patients resistant to checkpoint inhibitors; the Natural Killer (NK) Cell Priming Platform with INKmune to enhance NK cells against minimal residual disease in solid tumors such as metastatic castration-resistant prostate cancer; and the CORDStrom platform, a proprietary pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell (hucMSC) therapy that has completed a Phase II trial in recessive dystrophic epidermolysis bullosa (RDEB). Founded in 2015 and headquartered in Boca Raton, Florida, the company conducts clinical trials primarily in the United States and United Kingdom, targeting patients with advanced solid tumors, early-stage neurodegenerative diseases, and rare genetic skin disorders through precision medicine approaches that match drug mechanisms to patient biomarkers. Recent developments encompass a $19 million registered direct offering in June 2025 to support operations and R&D; a strategic manufacturing partnership with Cell and Gene Therapy Catapult (CGT Catapult) announced in 2025 for commercial-scale production of CORDStrom and other cell therapies ahead of planned Marketing Authorization Application (MAA) in the UK and Biologics License Application (BLA) submissions by mid-2026; presentation of new Phase II grey matter imaging data for XPro1595 at the CTAD conference in December 2025 reinforcing its potential in Alzheimer's; and ongoing high-level partnership discussions for XPro alongside preparation for an end-of-Phase II FDA meeting for the MINDFuL trial in Q4 2025.
Company News
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript
INmune Bio Q2 Earnings Call Highlights
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
INmune Bio's XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform